Press Releases

ALPHAEON Submits Biologics License Application for DWP-450 Neuromodulator BLA Submitted within Three Years of First Patient Enrollment

May 16, 2017

ALPHAEON Corporation (www.alphaeon.com) today announced that its wholly-owned subsidiary, Evolus Inc., submitted a Biologics License Application (BLA) for DWP-450, a Botulinum toxin Type A, to the U.S. Food and Drug Administration (FDA) seeking approval for the treatment of adult patients with glabellar lines, also known as “frown lines” between the eyebrows.

READ MORE

Show  

ALPHAEON Closes Convertible Note Financing

ALPHAEON Corporation (www.alphaeon.com) announced completion of a private placement of Secured Convertible Notes in a financing transaction led by existing investor Dental Innovations BVBA alongside Sailing Capital, Longitude Capital Management Co., LLC and other current investors. In addition to the funds provided at closing, future tranches of financing are subject to regulatory milestones related to its DWP-450 (Botulinum toxin Type A) product candidate for the treatment of adult patients with glabellar lines, also known as frown lines between the eyebrows. Specific terms of the transaction were not disclosed.

READ MORE



ShoutStore™ Adds Medline Products to E-commerce Platform for Doctors

IRVINE, Calif., Oct. 3, 2016 /PRNewswire/ -- ShoutStore, a rapidly growing e-commerce platform that is designed to transform how doctors and their staff discover and purchase medical products for their practice, announced today a new three-year partnership with Medline. Now, the global medical supplier's portfolio of disposable medical-surgical products, including exam gloves, bandages, gauze, gowns and testing kits, will be available to ShoutStore's 7,500 online members across the country.

READ MORE



ALPHAEON Appoints Murthy Simhambhatla PhD as CEO and President

Irvine, Calif., August 17, 2016 – ALPHAEON Corporation, a social commerce company in lifestyle healthcare, today announced that Murthy Simhambhatla PhD has been appointed CEO and President by the ALPHAEON Board of Directors. Dr. Simhambhatla replaces Robert E. Grant who was recently appointed as Vice Chairman of the ALPHAEON Board of Directors.

READ MORE



ALPHAEON Announces CEO’s Transition to Vice Chairman of the Board of Directors

Irvine, Calif., May 25, 2016 - ALPHAEON Corporation, a social commerce company, today announced that Robert E. Grant, the company’s founder and CEO, has decided to transition his role to become Vice Chairman of the ALPHAEON Board of Directors. Though planned for some time, this transition will be completed by June 30th.

READ MORE



ALPHAEON Launches PROVOQUE™ Facial Serum: Innovative Stem Cell-Derived Product Helps Reduce Signs of Aging in as Little as Two Weeks

IRVINE, Calif., May 10, 2016 – ALPHAEON Corporation today announced the launch of PROVOQUE™ Facial Serum, a patented stem cell-derived formula that helps address the visible signs of skin aging.

READ MORE



ALPHAEON Announces Results from Two Phase III Trials of DWP-450 Botulinum Toxin Type A

Irvine, Calif., April 7, 2016 - ALPHAEON Corporation today announced positive data from two Phase III clinical trials of its DWP-450 botulinum toxin type A neuromodulator at the American Society of Aesthetic Plastic Surgery meeting in Las Vegas, NV.

READ MORE



New Study Demonstrates the Superiority of Crosslinked Hyaluronic Acid in Improving the Skin Barrier Function

Irvine, Calif., April 4, 2016 – A new study* published in the Journal of Drugs in Dermatology titled “Pilot Comparative Study of the Topical Action of a Novel, Crosslinked Resilient Hyaluronic Acid on Skin Hydration and Barrier Function in a Dynamic, Three-Dimensional Human Explant Model” demonstrates that topically-applied crosslinked resilient Hyaluronic Acid (RHA™) is superior to non-crosslinked (linear) low and high molecular weight hyaluronic acid in increasing water content of the skin, maintaining skin integrity and improving skin barrier function.

READ MORE



ALPHAEON Introduces skIN3, A New Cosmetic Line Featuring DermaTriPlex™, A Unique Technology That Can Significantly Reduce the Appearance of Fine Lines and Wrinkles

Irvine, Calif., February 02, 2016 - ALPHAEON Corporation, a social commerce company and subsidiary of Strathspey Crown Holdings LLC, today announced the launch of skIN3, a new line of products featuring DermaTriPlex™, a unique technology that can offer consumers a breakthrough option to address the ongoing challenges of the visual signs of aging.

READ MORE



ALPHAEON Strengthens its Technology Foundation by Acquiring Eveo

IRVINE, Calif., Jan. 29, 2016 -- ALPHAEON Corporation, a social commerce company and subsidiary to Strathspey Crown Holdings LLC, today announced its acquisition of Eveo, an award-winning digital technology company. Terms of the acquisition were not disclosed.

READ MORE



ALPHAEON Strengthens Global Leadership with New Senior Appointments

Irvine, Calif., January 28, 2016 - ALPHAEON Corporation, a social commerce company and subsidiary to Strathspey Crown Holdings LLC, today announced it has strengthened its global leadership with the appointment of Clint Carnell as President of Europe, Middle East and Africa and David Barrios as Vice President of Canada and Latin America.

READ MORE



ALPHAEON Acquires Rocol SA

Irvine, Calif., December 18th, 2015 - ALPHAEON Corporation, a social commerce company and subsidiary to Strathspey Crown Holdings LLC, today announced its acquisition of Rocol SA, a leader in the commercialization of medical equipment across Latin America. Terms of the acquisition were not disclosed.

READ MORE



ALPHAEON Closes Acquisition of LENSAR

Irvine Calif., Dec. 17, 2015 - ALPHAEON Corporation, a social commerce company and subsidiary to Strathspey Crown Holdings LLC, today announced it has closed on its acquisition of LENSAR, Inc., a leading global developer and manufacturer of Femtosecond Lasers Systems (FLS), through a wholly owned subsidiary. Terms of the acquisition were not disclosed.

READ MORE



ALPHAEON and Zelegent Announce Exclusive Global Agreement to Commercialize Office-Based Snoring Therapy

Irvine, Calif., Dec. 15, 2015 ALPHAEON Corporation, a subsidiary of Strathspey Crown Holdings LLC, and Zelegent, Inc. jointly announced today that the two companies have entered into an exclusive worldwide agreement to bring Zelegent's office-based Elevoplasty technology to board certified sleep specialists.

READ MORE



ALPHAEON Appoints Former New Mexico Governor Bill Richardson and Sailing Capital Management CEO James Liu to Board of Directors

Irvine, Cailf., December 04, 2015 – ALPHAEON Corporation, a subsidiary of Strathspey Crown Holdings LLC, today named former Governor Bill Richardson and President and CEO of Sailing Capital Management, James Liu to its board of directors.

READ MORE



ALPHAEON to Acquire LENSAR

Irvine, Calif., November 16th, 2015 - ALPHAEON Corporation today announced the execution of a definitive agreement to acquire substantially all the assets of LENSAR, Inc., a leading global developer and manufacturer of Femtosecond Laser Systems (FLS), through a wholly owned subsidiary. The transaction is valued at up to $59 million in cash, stock and assumed debt. The transaction is subject to the completion of certain closing conditions on or before December 31, 2015.

READ MORE



ALPHAEON Announces Agreement with PhysIOL to Commercialize Advanced Trifocal IOL Technology

IRVINE, Calif., Nov. 14, 2015 /PRNewswire/ -- ALPHAEON Corporation today announced it has entered into a definitive agreement with PhysIOL SA of Belgium, to jointly develop and commercialize an exclusive ALPHAEON-branded Trifocal lens technology. Specific terms of the agreement were not disclosed.

READ MORE



ALPHAEON Corporation Closes Series B Preferred Stock Financing

IRVINE, Calif., Nov. 12th, 2015 -- ALPHAEON Corporation today announced that it has completed a private placement of Series B Preferred Stock in a transaction led by Sailing Capital. H&S Ventures LLC, Longitude Capital and Chow Tai Fook Enterprises also participated in the Series B. Specific terms of the transaction were not disclosed.

READ MORE



ALPHAEON Announces Plan to Acquire Integrity Digital Solutions

Irvine, Calif., November 12th, 2015 - ALPHAEON Corporation today announced its plan to acquire Integrity Digital Solutions LLC, for an undisclosed sum. The consummation of the acquisition is subject to requisite approval from both companies and the satisfactory completion of certain closing conditions. The transaction is expected to close on or before December 31st 2015.

READ MORE



Physician Recommended Nutriceuticals Receives U.S. Patent for its Unique 3:1 Omega 3 Composition

Irvine, Calif., November 10, 2015 – ALPHAEON Corporation and its subsidiary company PRN Physician Recommended Nutriceuticals, LLC (PRN), a leading provider of nutritional supplements, today announced that the U.S. Patent and Trademark Office issued to PRN U.S. Patent No. 9,115,078 “Compositions for Improving the Quality of the Meibum Composition of Inflamed or Dysfunctional Meibomian Glands.”

READ MORE



Physician Recommended Nutriceuticals Named to Inc. 5000 Fastest-Growing Private Companies List for Fourth Consecutive Year

Irvine, Cailf., November 06, 2015 – ALPHAEON Corporation’s subsidiary PRN Physician Recommended Nutriceuticals, LLC, a leading provider of nutritional supplements, has earned a position on the Inc. 5000 list for the fourth consecutive year. Inc. 5000 recognizes the fastest growing companies In America based on percentage growth of revenue for participating companies.

READ MORE



ALPHAEON Launches ShoutMD 3.0, the First Social Commerce Store for Lifestyle Healthcare Products

ALPHAEON Corporation, a leader in self-pay healthcare social commerce, announced the release of ShoutMD 3.0. ShoutMD is a unique professional and social network that allows board certified physician specialists to share insights, start discussions, and collaborate with their peers with the goal of improving patient experiences and outcomes.

READ MORE



ALPHAEON’s Innovative Approach to Skin Health has Arrived

Irvine, Cailf., July 9, 2015 – ALPHAEON Corporation announced today the launch of Skin Essentials Omega Advantage™, the first product under its new Skin Essentials product line. ALPHAEON, in collaboration with its subsidiary company PRN Physician Recommended Nutriceuticals (“PRN”), a leading provider of nutritional supplements, introduced Skin Essentials Omega Advantage, a nutritional supplement designed to support skin health.

READ MORE



TouchMD Unveils New State-of-the-Art Platform at ASAPS

Irvine, Calif., May 15, 2015 – ALPHAEON Corporation, a leader in self-pay healthcare social commerce, today announced they are unveiling the new TouchMD® platform at the annual American Society of Aesthetic Plastic Surgeons meeting in Montreal. TouchMD version 4 brings a full redesign of the patient consultation platform, with an enhanced visual experience through new layouts that showcase practice content and maximize screen space, intuitive navigation allowing for quick access to all images and content, built-in advanced drawing tools, and the ability to brand and customize the platform for each practice.

READ MORE



ALPHAEON Appoints Hon. Christopher Cox and Dennis Wolf to Board of Directors

Irvine, Calif., May 6, 2014 – ALPHAEON Corporation, a leader in self-pay healthcare social commerce, today named Christopher Cox and Dennis Wolf to its board of directors.

READ MORE



ALPHAEON Completes Enrollment in US Pivotal Trials for EVOLUS Neuromodulator

Irvine, Calif., April 24, 2015 – ALPHAEON Corporation announced today that they completed enrollment of two pivotal studies with their Botulinum toxin Type A neuromodulator, EVOLUS, for the treatment of glabellar lines. Completing enrollment marks a significant milestone for the Phase III development program.

READ MORE



PRN's Omega-3 Hits Major Endpoints Against Placebo in a Study of Dry Eye Symptoms

Irvine, Cailf., April 17, 2015 – ALPHAEON Corporation and its subsidiary company PRN Physician Recommended Nutriceuticals, a leading provider of nutritional supplements, announced today the upcoming presentation of a new study assessing the effect of oral re-esterified triglyceride omega-3 fatty acids for patients with dry eye symptoms and meibomian gland dysfunction.

READ MORE



ALPHAEON Expands ALPHAEONMD Practice System with Launch of ENGAGEMD

Irvine, CA, April 16, 2015 – ALPHAEON® Corporation announced today the launch of EngageMD™, a premier cloud-based patient relationship management (PRM) and marketing platform. EngageMD is ALPHAEON’s second major technology solution, expanding the ALPHAEONMD™ suite of integrated services designed to improve patient experience, practice productivity and growth.

READ MORE



ALPHAEON Appoints Jeff Castillo as President of the Americas and Kuntal Joshi as President of Asia Pacific

Irvine, Calif., January 28, 2015 – ALPHAEON Corporation announced today that Jeff Castillo has joined the organization as President of the Americas, and Kuntal Joshi has joined as President of Asia Pacific. Mr. Castillo and Mr. Joshi each bring more than 25 years of experience in the medical device sector to their roles at ALPHAEON.

READ MORE



ALPHAEON Begins Phase III Study for its Neurotoxin, EVOSYAL

IRVINE, Calif., January 22, 2015, - ALPHAEON® Corporation announced today that the U.S. Food and Drug Administration (FDA) agreed to the protocol for its phase III clinical study of EVOSYAL™, to treat glabellar lines. ALPHAEON acquired the exclusive U.S. and certain international distribution rights to EVOSYAL, a Botulinum toxin Type A neuromodulator, as part of its acquisition of Evolus Inc. In the last 12 months, ALPHAEON has submitted its investigational new drug application for EVOSYAL and completed enrollment in its phase II study.

READ MORE



ALPHAEON Partners with Tracey Technologies to Sell Next-Generation iTRACE Platform

IRVINE, Calif., January 16, 2015, - ALPHAEON® Corporation announced today that it has entered into a co-promotion agreement with Tracey Technologies Corporation, a developer and manufacturer of advanced refractive diagnostic devices, to market the next generation iTrace® platform. “iTrace is a great complement to our developing ophthalmic technology offering, integrating with TouchMD® to further enhance the patient education experience,” said Robert E. Grant, CEO of ALPHAEON. “We believe it will be a catalyst for ophthalmologists to grow their premium, custom procedures including Refractive Lens Exchange and LASIK.”

READ MORE



ALPHAEON Corporation Closes Series A Preferred Stock Financing in a Transaction led by Longitude Capital Management Co., LLC.

IRVINE, Calif., January 15, 2015 ALPHAEON® Corporation, a subsidiary of Strathspey Crown Holdings LLC, announced that it has completed a private placement of Series A Preferred Stock in a transaction led by Longitude Capital Management Co., LLC. Specific terms of the transaction were not disclosed. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

READ MORE



ALPHAEON Completes Acquisition of Clarion Medical Technologies for $55 Million

ALPHAEON® Corporation, a subsidiary of Strathspey Crown Holdings LLC, announced today that it has acquired Clarion Medical Technologies® Inc., a leading provider of medical and aesthetic equipment and consumables in Canada for $55 million in a combination of cash and equity plus performance-based earn outs. Clarion has more than 100 employees, 36 sales representatives and over 40 product licenses. The acquisition expands ALPHAEON’s global position. ALPHAEON believes that combining its unique platforms, including ShoutMD™, with the Clarion product offering will increase connectivity with physicians and could expand the market potential.

READ MORE



ALPHAEON Acquires TouchMD and its State-Of-The-Art Patient Consultation Platform

ALPHAEON® Corporation, a leader in lifestyle healthcare and subsidiary of Strathspey Crown Holdings LLC, announced today that it has acquired TouchMD™ for $22 million. TouchMD is an interactive software platform that helps specialty physicians educate patients before, during and after practice consultation, which enhances the patient experience and increases conversion rates.

READ MORE



ALPHAEON Partners with Physician CEO Program

ALPHAEON® Corporation, a leader in lifestyle healthcare and a subsidiary of Strathspey Crown Holdings LLC, and SurgiVision® Consultants, Inc., a consulting firm contributing to the advancement of refractive surgery and ophthalmology through innovation and education, announced today a partnership to promote the Physician CEO™ program. The Physician CEO program is a new Certification Program at the Kellogg School of Management at Northwestern University that provides executive business training for physicians in the cash-pay sector of medicine.

READ MORE



ALPHAEON to Acquire Clarion Medical Technologies

ALPHAEON® Corporation, a leader in lifestyle healthcare and subsidiary of Strathspey Crown Holdings LLC, and Clarion® Medical Technologies Inc. today announced that they have entered into a definitive agreement for ALPHAEON to acquire all of the outstanding shares and assets of Clarion, the leading provider of medical and aesthetic equipment and consumables in Canada, for an undisclosed sum. The acquisition is expected to close on or before September 30, 2014.

READ MORE



FDA Accepts Investigational New Drug Application for ALPHAEON’S Neurotoxin Evosyal

ALPHAEON® Corporation, a leader in lifestyle healthcare and subsidiary of Strathspey Crown Holdings LLC, announced today that the U.S. Food and Drug Administration (FDA) accepted the Investigational New Drug (IND) application to conduct clinical studies for EVOSYAL™, an advanced Botulinum toxin Type A neurotoxin that was acquired by ALPHAEON last October, as part of the acquisition of Evolus Inc.

READ MORE



ALPHAEON Turns Innovation Into Reality with TEDxOrangeCoast

ALPHAEON® Corporation, an innovator in lifestyle healthcare, is partnering with TEDxOrangeCoast for the fourth annual conference, giving innovators a platform to share inspiring ideas with a focus on uncovering the next tipping points. TEDxOrangeCoast is an independently organized event licensed by TED.

READ MORE



ALPHAEON Seeks to Rewards Innovative Teens

ALPHAEON® Corporation, a leader in lifestyle healthcare announced today that it is sponsoring the Fall 2014 TEDx TeenChallenge. ALPHAEON, in collaboration with TEDx OrangeCoast, is challenging teens between the ages of 13 to 19 to develop a technical application, device or idea that benefits society. Special focus will be given to submissions of original ideas around light and sound.

READ MORE



ALPHAEON Acquires PRN, A Leading Specialty Nutriceutical Company

ALPHAEON Corporation, a leader in lifestyle healthcare and subsidiary of Strathspey Crown Holdings LLC, announced today that it has acquired Physician Recommended Nutriceuticals (PRN), a leading developer of specialty omega-3s, and related products for dry eye and macular degeneration, based in Plymouth Meeting, PA, in a transaction worth up to $55M.

READ MORE



ALPHAEON Director Named To “The Ophthalmologist's” 2014 Power List

ALPHAEON Corporation, an emerging leader in lifestyle healthcare and subsidiary of Strathspey Crown Holdings LLC, is pleased to announce that board director Dr. Richard Lindstrom has been recognized by The Ophthalmologist, an international publication based in the UK, as the fourth most influential person in the field of ophthalmology. The publication issues its power 100 list each year based on a nomination and judging process.

READ MORE



ALPHAEON Appoints Board of Directors

ALPHAEON Corporation, an emerging leader in lifestyle healthcare and subsidiary of Strathspey Crown Holdings LLC, today named a team of prominent leaders in healthcare and business to its board of directors. In addition, the Honorable Christopher Cox will serve as a special advisor to the board.

READ MORE



ALPHAEON Launches New Patient Financing Solution

ALPHAEON Corporation, a leader in lifestyle healthcare and subsidiary of Strathspey Crown Holdings, LLC, announced today the launch of ALPHAEON CREDIT™*, a new tool for patients seeking to finance self-pay lifestyle healthcare procedures through board-certified specialty physicians in dermatology, ophthalmology, plastic surgery and facial plastic surgery.

READ MORE



ALPHAEON Announces Appointment of Medical Aesthetics Industry Veteran Bob Rhatigan as Chief Operating Officer

ALPHAEON Corporation, a leader in lifestyle healthcare and subsidiary of Strathspey Crown Holdings LLC, announced today that Bob Rhatigan has joined the company as Chief Operating Officer. In his new position, Mr. Rhatigan will play a key role in the development of ALPHAEON’s commercial execution and future growth.

READ MORE



ALPHAEON Expands Partnership with TEOXANE Laboratories

ALPHAEON Corporation, a leader in lifestyle healthcare and a wholly-owned subsidiary of Strathspey Crown Holdings LLC, announced today a significant expansion of its partnership with Geneva-based TEOXANE Laboratories.

READ MORE



ALPHAEON Launches State-of-the-Art Interactive Platform in Ophthalmology

ALPHAEON Corporation, a leader in lifestyle healthcare and wholly-owned subsidiary of Strathspey Crown Holdings LLC, announced today that it will launch TouchMD™, a premier ophthalmology practice development platform, this week at the annual American Society of Cataract and Refractive Surgery (ASCRS) meeting (held in Boston, MA).

READ MORE



ALPHAEON Acquires Exclusive License to Advanced Technology For Vision Correction

ALPHAEON Corporation, a leader in lifestyle healthcare and wholly-owned subsidiary of Strathspey Crown Holdings LLC, announced today that it has acquired an exclusive U.S. license from SCHWIND eye-tech solutions GmbH & Co. KG to market the AMARIS® excimer laser system, for an undisclosed amount.

READ MORE



ALPHAEON Acquires Exclusive Worldwide Licensing Rights to TouchMD

TouchMD is an interactive software platform that helps specialty physicians educate patients.

READ MORE



ALPHAEON to Launch the First Early Cataract Detection Device

ALPHAEON Corporation, announced today that it has acquired an exclusive U.S. license from Visiometrics, S.L. to market the HD Analyzer™, for an undisclosed amount.

READ MORE



Strathspey Crown Acquires Evolus, Inc.

ALPHAEON has acquired the exclusive license to market an advanced Botulinum toxin Type A neurotoxin.

READ MORE



ALPHAEON Acquires Exclusive United States License to Teoxane Laboratories' Full Portfolio of Next-Generation Dermal Fillers and Cosmeceutical Products

TEOXANE is a recognized innovator of hyaluronic acid-based products.

READ MORE



Strathspey Crown Establishes ALPHAEON Corporation, the First Self-Pay Lifestyle Healthcare Company

ALPHAEON is a unique, patient-centered company operating only in lifestyle healthcare.

READ MORE



Strathspey Crown Announces Appointment of Vikram Malik as a Managing Partner

Vikram Malik will play a strategic role as the firm grows and expands within the lifestyle healthcare sector.

READ MORE



Media Coverage

Lifestyle Medicine and the Non-reimbursed Space: ALPHAEON's Model

April 17, 2015

Host Steve Dayan, MD takes viewers inside ALPHAEON Corp. in an exclusive interview with CEO Robert E. Grant. ALPHAEON's business model focuses on the non-reimbursed space with an emphasis on lifestyle medicine.

WATCH NOW

Show  

ALPHAEON’s Grant Explains Innovative New Model - Podcast

ALPHAEON is tapping physicians for unprecedented involvement in finding and funding new treatments. Hear how the company sees the future of healthcare.

LISTEN HERE



Strathspey Crown's Mission is to Make MDs Independent

Two years ago, Strathspey Crown established ALPHAEON Corporation to promote the benefits of self-pay procedures for patients and medical practices.

READ MORE



Vogue: "Water Works: How the World’s Oldest Skin Care Ingredient Is Making a Comeback"

The top beauty companies are racing to find new ways to make water perform more effectively—launching a new wave of innovative face serums, elixirs, and masks that’s taking its hydrating potential to the next level.

READ MORE



Company to Watch: Strathspey Crown Holdings LLC

This Newport Beach-based private equity investor got the nod as the company to watch in 2014 based on our belief that it would be on the lookout for more deals in the "lifestyle medicine" arena.

READ MORE



W Magazine: "Deep Water"

The latest moisturizers, reports Katie Becker, are made to get under your skin

READ MORE



Insider Skin Savers

Women in the know are talking about the new complexion perfecters sold exclusively at dermatologist' offices

READ MORE



The Power List 2014

Who are the 100 most influential people in ophthalmology? That’s the question we posed to ourselves – and then to you – over two months ago, ahead of open nominations and a painstaking judging process. Here, without further ado, we celebrate the answer.

READ MORE



Healthcare Startup to Move Into Lakeshore Towers

ALPHAEON Corp., a startup lifestyle healthcare company...has signed a deal to move its growing operations to Lakeshore Towers office complex in Irvine.

READ MORE



The Power of 3. Is three the magic number when it comes to neurotoxins?

Physicians compare the merits of Botox Cosmetic, Dysport and Xeomin, as new wave of toxins vies for approval.

READ MORE



A new twist in aesthetic medicine: ALPHAEON sets its sights on Europe

Wendy Lewis talks to Teoxane Founder Valerie Taupin about her partnership with ALPHAEON.

READ MORE



Popular European Wrinkle Filler Making its Way to the U.S.

PSC’s Dr. Bruce Van Natta of Indianapolis, Indiana interviews Valérie Taupin, founder and CEO of Teoxane Laboratories from Geneva, Switzerland to discuss the cosmetic line and dermal filler product that’s making its way to the U.S.

READ MORE



ALPHAEON named "BEST INDUSTRY START-UP of 2013"

Plastic Surgery Practice named ALPHAEON the Best Industry Start-Up of 2013. "This 'lifestyle healthcare company' brought to us by former Allergan Medical President Robert E. Grant is most certainly one to watch."

READ MORE



Laser Licensing Pushes ALPHAEON's Middleman Method

ALPHAEON acquired the U.S. licensing rights to the Amaris excimer laser device this month from Germany-based Schwind eye-tech-solutions GMBH.

READ MORE



ALPHAEON Sets New Standard In Supporting Innovation Among Physicians

As the healthcare system in the U.S. evolves via the implementation of the Affordable Care Act (ACA), ALPHAEON Corp. (Newport Beach, Calif.) is a new company designed to support an emerging tier of self-pay patients.

READ MORE



Seeking ALPHAEON

You've likely heard the buzz about ALPHAEON, and now it's time to get to know the lifestyle healthcare marketing company that has been turning heads and grabbing headlines since its inception.

READ MORE



Beautiful Minds are Free from Fear: Robert Grant at TEDx

Robert E. Grant, CEO of ALPHAEON, shares what makes a beautiful mind: any moment free from fear is an opportunity to taste immortality and new possibilities.

WATCH NOW



ALPHAEON, Backed by Strathspey Crown, to Build Specialty Medical Franchise with Acquisitions, CEO Says

Robert Grant expects to continue its acquisition pace to build a national franchise operated by specialty medical physicians.

READ MORE



ALPHAEON Corp. Goes to Switzerland for First Product

ALPHAEON has acquired the licensing rights for a line of lower-face skin fillers and “cosmeceuticals” from TEOXANE Laboratories.

READ MORE



Growth Equity Firm Launches ALPHAEON to Advance Products in Self-Pay Health Care Sector

The vision of ALPHAEON is to encourage the development of forward-thinking medical advances that enhance patients' lives.

READ MORE



Link Takes Personal Interest in Strathspey's Self-Pay Play

William Link, a managing director of Versant Ventures, has been named chairperson of ALPHAEON.

READ MORE



The American Society of Plastic Surgeons and Strathspey Crown Announce a Strategic Partnership that Benefits Plastic Surgery Practices

The partnership will jointly invest and work together on a number of programs, including group purchasing and licensing.

READ MORE



Disclaimer: ALPHAEON’s website provides links to other webpages. When you click on these links you will leave ALPHAEON’S website and will be redirected to another site. Please be aware that the security and privacy policies and terms of use on these sites may be different than ALPHAEON’S policies, so please read privacy and security policies and terms of use for the linked site closely.